Thrombocytopenia Clinical Trial
Official title:
Sirolimus in Patients With Connective Tissue Disease Related Thrombocytopenia (CTD-TP): a Single-arm, Open-label Clinical Trial in China
We have designed a single-arm, open-label study of sirolimus in Chinese patients with refractory CTD-TP unresponsive to, or intolerant of, conventional medications at Peking Union Medical College Hospital (PUMCH). Patients received oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL. Patients were treated with sirolimus for more than 6 months. Safety outcomes and the efficacy endpoints were assessed in all patients who received at least one dose of treatment.
Connective tissue disease related thrombocytopenia (CTD-TP) is one of the common visceral
complications of connective tissue diseases (CTD) with a poor response to traditional
therapy. To date, some successful cases were reported in sirolimus treating refractory CTD-TP
as a newly therapeutic method. However, there is still a lack of prospective clinical trials.
This study aims to evaluate the efficacy of sirolimus in the treatment of refractory CTD-TP.
To investigate this issue, investigators have designed a single-arm, open-label clinical
trial of refractory CTD-TP patients in Peking Union Medical College Hospital (PUMCH). In this
study, the researchers will enroll 20 patients who have a poor response to at least 6 months'
traditional treatment. The participants will receive oral sirolimus treatment for 12 months.
The primary end point is the change of platelet count in CBC. Secondary end points include
the change of CTD activity, the time to disease complete remission and all-cause serious
adverse events (SAE).
Research Question:
Does sirolimus improve the prognosis in patients with connective tissue disease related
thrombocytopenia (CTD-TP) in Chinese patients?
Specific aims:
1. To determine the efficacy of sirolimus for the treatment of CTD-TP in Chinese patients
2. To evaluate the safety of sirolimus for the treatment of CTD-TP in Chinese patients
3. To analyze the clinical characteristics of CTD-TP in the sirolimus effective patients
Methods:
This is a prospective open-label trial in a period of 12 months. Thrombocytopenia is defined
that the count of platelet is less than 100×109/L. CTDs include SLE, pSS, RA, scleroderma,
RA, dermatomyositis and MCTD. The newly diagnosed CTD-TP patients who have received no
steroid or IS treatment will be ruled out the trial. All the participants should fulfill one
of the criteria of SLE, pSS, RA, scleroderma, RA, dermatomyositis and MCTD and suffer from
refractory TP, or be diagnosed CTD-associated TP by two experimental rheumatologists. The
current standard treatment for CTD-TP is glucocorticoid plus one kind of immunosuppressant.
The patients who still have TP after more than 3 months' standard treatment will be included
into the trial. After signing informed consent forms, participants will receive oral
sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day,
with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
Baseline data will be collected at enrollment. All participants will finish their 5 follow-up
assessments (1st mon, 2nd mon, 4th mon, 6th mon and 12th mon) in 12 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT03633019 -
High-dose Use of rhTPO in CIT Patients
|
Phase 4 | |
Recruiting |
NCT06087198 -
Clinical Performance Evaluation of T-TAS®01 HD Chip
|
||
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Completed |
NCT02845609 -
Efficacy of Sialic Acid GNE Related Thrombocytopenia
|
Phase 2 | |
Recruiting |
NCT02241031 -
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
|
Phase 2/Phase 3 | |
Recruiting |
NCT02244658 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
|
Phase 3 | |
Completed |
NCT01356576 -
Effect of Hemodialysis Membranes on Platelet Count
|
N/A | |
Terminated |
NCT01368211 -
Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)
|
Phase 2/Phase 3 | |
Unknown status |
NCT01196884 -
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
|
||
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A | |
Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
Not yet recruiting |
NCT06036966 -
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients
|
Phase 2 | |
Completed |
NCT01791101 -
Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.
|
Phase 2 | |
Recruiting |
NCT06053021 -
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
|
N/A | |
Recruiting |
NCT03701217 -
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05958511 -
Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients
|
||
Completed |
NCT04917679 -
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
|
Phase 2 |